WCM
RLAY icon

WealthTrak Capital Management’s Relay Therapeutics RLAY Stock Holding History

WealthTrak Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30
Closed -$124 – 1091
2024
Q4 		$124 Buy
+30
New +$163 ﹤0.01% 879

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

WealthTrak Capital Management's RLAY Position: Q1 2025 in Review

WealthTrak Capital Management sold out of Relay Therapeutics (RLAY) in Q1 2025, closing a stake of 30 shares — an estimated $124 sold.

WealthTrak Capital Management first reported a position in RLAY in Q4 2024 and held it in 1 quarter. The position peaked at $124 in Q4 2024. 207 funds tracked by Wall St. Rank hold RLAY as of Q1 2025.

  • WealthTrak Capital Management reported no remaining Relay Therapeutics position as of Q1 2025 after selling out during the quarter.
  • WealthTrak Capital Management sold 30 Relay Therapeutics shares in Q1 2025, an estimated $124.
  • WealthTrak Capital Management first reported a position in Relay Therapeutics in Q4 2024 and held it in 1 quarter.
  • WealthTrak Capital Management's Relay Therapeutics position peaked at $124 in Q4 2024.
  • 207 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2025.

Based on WealthTrak Capital Management's 13F filing for Q1 2025, filed 15 May 2025.